Search results for "Withdrawal"

showing 10 items of 97 documents

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

2018

It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TK…

MaleImatinib mesylate discontinuation; chronic myelogenous leukemia; treatment-free remission; long-term outcomes; molecular response; cml patients; recommendations; management; dasatinib; cessationchemistry.chemical_compound0302 clinical medicineTreatment Free RemissionPregnancyMED/15 - MALATTIE DEL SANGUEInterquartile rangeingleseMedicinedasatinibChronic Myelogenous Leukemiatreatment-free remissionPonatinibmolecular responseHematologyMiddle AgedProtein-Tyrosine Kinasescml patientsDasatinibTreatment OutcomeLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylateFemaleChronic Myelogenous Leukemia; Discontinuation; Treatment Free Remissionlong-term outcomesmanagementmedicine.drugAdultmedicine.medical_specialtyChronic Myeloid LeukemiaSocio-culturaleDiscontinuationArticletyrosine kinase inhibitors discontinued treatment chronic myeloid leukemia treatment-free remission (TFR)Safety-Based Drug Withdrawals03 medical and health scienceschronic myeloid leukemia tyrosine kinase inhibitors discontinuationMedian follow-upLeukemia Myelogenous Chronic BCR-ABL PositiveInternal medicineImatinib mesylate discontinuationHumansProtein Kinase InhibitorsRetrospective Studiesbusiness.industryImatinibmedicine.diseaseDiscontinuationrespiratory tract diseasesSettore MED/15 - MALATTIE DEL SANGUEcessationNilotinibchemistryrecommendationsbusiness030215 immunologyChronic myelogenous leukemia
researchProduct

Environment associated with morphine and experience of aggression modulate behaviors of postdependent mice

2002

Contexts associated with drug use can acquire secondary reinforcing properties. Furthermore, context-specific withdrawal has been observed to reflect a relatively long-lasting learned response. The aim of this study was to evaluate the effect of the environment paired with morphine after 15 days of abstinence. In the first experiment, isolated male mice received saline or morphine either in their home cage or in the distinctive environment, performing two agonistic encounters in the distinctive environment during spontaneous withdrawal. Similar groups were assigned but without aggression encounters during withdrawal. In the second experiment, animals received saline or morphine as previousl…

MaleNarcotic Antagonistsmedicine.medical_treatmentmedia_common.quotation_subjectPhysiologyContext (language use)EnvironmentMiceRewardTremormedicineAgonistic behaviourAnimalsWeaningSingle-Blind MethodSalinemedia_commonMorphineNaloxoneAggressionGeneral NeuroscienceConvalescenceConvalescenceAbstinenceHousing AnimalSubstance Withdrawal SyndromeAnesthesiaMorphinemedicine.symptomPsychologyMorphine DependenceAgonistic Behaviormedicine.drugBrain Research Bulletin
researchProduct

The dopamine release inhibitor CGS 10746B blocks conditioned physical signs of morphine withdrawal

2003

Environment previously paired with morphine withdrawal leads to conditioned physical signs of withdrawal, this effect being modulated by additional exposition to morphine administration. In this study, the putative role of dopamine in conditioned withdrawal signs is evaluated by administering the dopamine release inhibitor CGS 10746B prior to suffering two naloxone-induced withdrawals in a distinctive environment associated or not with morphine administration. The results show that dopamine seems to be necessary for the development of conditioned somatic signs of morphine withdrawal, as animals which received CGS 10746B do not present paw tremor or body shakes when they are placed in the en…

MaleNarcoticsPharmacologyBehavior AnimalMorphineNaloxoneThiazepinesNarcotic AntagonistsMedicine (miscellaneous)PharmacologySubstance Withdrawal SyndromeMicePsychiatry and Mental healthMorphine withdrawalDopamineConditioning PsychologicalMorphinemedicineAnimalsConditioningSocial BehaviorPsychologymedicine.drugAddiction Biology
researchProduct

Memantine presents different effects from MK-801 in motivational and physical signs of morphine withdrawal

2003

Adaptive changes in neural systems due to chronic opiate exposure are related to the neural plasticity phenomenon, NMDA receptors being implicated in these processes, e.g. tolerance, dependence or withdrawal. In this work, we investigated the effect of two non-competitive NMDA antagonists, memantine and MK-801, in motivational (Conditioned Place Aversion paradigm, CPA) and physical aspects of morphine withdrawal. After the induction of morphine dependence, animals in which the CPA was studied, received memantine (5 and 10 mg/kg) or MK-801 (0.3-0.006 mg/kg) either during the acquisition (conditioning) or expression (test) phase of this procedure. Both drugs were capable of inhibiting conditi…

MaleNarcoticsTime FactorsNarcotic AntagonistsMotor ActivityPharmacologyMiceBehavioral NeuroscienceMemantineConditioning PsychologicalNeuroplasticitymedicineAnimalsDrug InteractionsBehavior AnimalDose-Response Relationship DrugMorphineNaloxoneKindlingMemantineSubstance Withdrawal SyndromeBlockadeMorphineNMDA receptorConditioningDizocilpine MaleateOpiatePsychologyExcitatory Amino Acid AntagonistsMorphine Dependencemedicine.drugBehavioural Brain Research
researchProduct

Isolation decreases physical and motivational aspects of morphine withdrawal

2005

Environmental manipulations such as social housing conditions of animals may play a role in the expression of individual differences in response to drugs. This study aimed to evaluate whether isolated and grouped mice develop different degrees of morphine dependence. Isolated and grouped mice were rendered morphine dependent employing two different methods of induction: a fast or slow protocol, both reaching the same maximum daily dose (100 mg/kg). Naloxone-induced morphine withdrawal was assessed using a modified Gellert-Holtzman scale and a conditioned place aversion (CPA) procedure. Isolated animals manifested fewer signs of physical dependence than grouped mice and only those receiving …

MaleNarcoticsmedicine.medical_specialtyEndogenous OpiatesAnalgesicPhysical dependencePharmacologyMiceMorphine withdrawalInternal medicinemedicineAnimalsConditioned place aversionPharmacologyMorphineMorphine dependenceDrug administrationSubstance Withdrawal SyndromePsychiatry and Mental healthEndocrinologySocial IsolationMorphineAnalgesiamedicine.symptomPsychologymedicine.drugBehavioural Pharmacology
researchProduct

Effects of SCH 23390, Raclopride, and Haloperidol on Morphine Withdrawal-Induced Aggression in Male Mice

1999

Abstract RODRIGUEZ-ARIAS, M., J. PINAZO, J. MINARRO AND L. STINUS. Effects of SCH 23390, raclopride, and haloperidol on morphine withdrawal-induced aggression in male mice. PHARMACOL BIOCHEM BEHAV 64(1) 123–130, 1999.—Dopamine seems to play a very important role in aggressive behavior observed in morphine withdrawal. The effect of SCH 23390 (0.5 mg/kg), raclopride (0.3 mg/kg), and haloperidol (0.1 mg/kg) on morphine withdrawal-induced aggression has been studied in this work. Mice were rendered dependent by a daily injection of morphine (2.5 mg/kg) for 14 days. Three different experiments were carried out with the objective to evaluate the antiaggressive effect of the dopamine antagonists o…

MaleNarcoticsmedicine.medical_specialtyNarcotic AntagonistsClinical BiochemistryPharmacologyToxicologyBiochemistryMiceBehavioral Neurosciencechemistry.chemical_compoundDopamineInternal medicineSalicylamidesmedicineHaloperidolAnimalsSocial BehaviorBiological PsychiatryPharmacologyRacloprideSCH-23390MorphineNaloxonebusiness.industryDopaminergicAntagonistDopamine antagonistBenzazepinesSubstance Withdrawal SyndromeAggressionEndocrinologychemistryRacloprideMorphineDopamine AntagonistsHaloperidolbusinessAntipsychotic Agentsmedicine.drugPharmacology Biochemistry and Behavior
researchProduct

Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine.

2013

This study was aimed to evaluate the involvement of CB2 cannabinoid receptors (CB2r) in the rewarding, reinforcing and motivational effects of nicotine. Conditioned place preference (CPP) and intravenous self-administration experiments were carried out in knockout mice lacking CB2r (CB2KO) and wild-type (WT) littermates treated with the CB2r antagonist AM630 (1 and 3 mg/kg). Gene expression analyses of tyrosine hydroxylase (TH) and α3- and α4-nicotinic acetylcholine receptor subunits (nAChRs) in the ventral tegmental area (VTA) and immunohistochemical studies to elucidate whether CB2r colocalized with α3- and α4-nAChRs in the nucleus accumbens and VTA were performed. Mecamylamine-precipitat…

MaleNicotinemedicine.medical_treatmentNicotinaRecompensa (Psicologia)Self AdministrationPharmacologyNucleus accumbensNucleus AccumbensNicotineReceptor Cannabinoid CB2MiceRewardCannabinoides -- ReceptorsmedicineAnimalsAcetylcholine receptorPharmacologyMice KnockoutTyrosine hydroxylaseVentral Tegmental Areamedicine.diseaseConditioned place preferenceSubstance Withdrawal SyndromeVentral tegmental areaPsychiatry and Mental healthmedicine.anatomical_structureNicotine withdrawalConditioning OperantOriginal ArticleCannabinoidPsychologyReinforcement Psychologymedicine.drugNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
researchProduct

Different brain oxidative and neuroinflammation status in rats during prolonged abstinence depending on their ethanol relapse-like drinking behavior:…

2022

Rationale: Accumulating evidence suggests that chronic alcohol consumption is associated with excessive oxidative damage and neuroinflammatory processes and these events have been associated to early alcohol withdrawal. In the present research we wonder if brain oxidative stress and neuroinflammation remains altered during prolonged withdrawal situations and whether these alterations can be correlated with relapse behavior in alcohol consumption. The effects of alcohol reintroduction were also evaluated Methods: We have used a model based on the alcohol deprivation effect (ADE) within a cohort of wild-type male Wistar rats. Two subpopulations were identified according to the alcohol relapse…

MalePharmacologyAlcohol Efectes fisiològicsAlcohol DrinkingEthanolEstrès oxidatiuPrefrontal CortexToxicologyRatsSubstance Withdrawal SyndromeAlcoholismOxidative StressPsychiatry and Mental healthAlcohol relapseAlcohol deprivation effectNeuroinflammationRecurrenceOxidative stressNeuroinflammatory DiseasesAnimalsPharmacology (medical)Rats WistarOxidation-ReductionCraving
researchProduct

Effects of desipramine and alprazolam in the forced swim test in rats after long-lasting termination of chronic exposure to picrotoxin and pentylenet…

1993

Abstract Rats were treated for 5 weeks with three subconvulsant doses of picrotoxin (PTX) and pentylenetetrazol (PTZ) per week to induce a persistent reduction of the GABA A receptor function which results in chemical kindling. Fifteen days after termination of this treatment schedule, the effect of desipramine (DMI) and alpraxolam (ALP) on immobility time in the forced swim test (FST) was evaluated. Chronic PTX and PTZ did not alter the immobility time. Acute PTX and PTZ reduced the immobility of rats chronically treated with vehicle but not of those exposed chronically to PTX and PTZ. Chronic PTX did not influence the anti-immobility effect of DMI, but blocked that of ALP. Chronic PTZ mar…

MalePharmacologyMotor ActivityChlordiazepoxidechemistry.chemical_compoundDesipraminemedicineAnimalsPicrotoxinPharmacology (medical)GABA-A Receptor AntagonistsPentylenetetrazolBiological PsychiatrySwimmingPharmacologyAlprazolamGABAA receptorKindlingbusiness.industryDesipramineChlordiazepoxideRatsSubstance Withdrawal SyndromePsychiatry and Mental healthNeurologyAlprazolamchemistryPentylenetetrazoleNeurology (clinical)businesshuman activitiesPsychomotor Performancemedicine.drugBehavioural despair testPicrotoxinEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Adolescent but not adult ethanol binge drinking modulates cocaine withdrawal symptoms in mice.

2016

Background Ethanol (EtOH) binge drinking is an increasingly common behavior among teenagers that induces long-lasting neurobehavioral alterations in adulthood. An early history of EtOH abuse during adolescence is highly correlated with cocaine addiction in adulthood. Abstinence of cocaine abuse can cause psychiatric symptoms, such as anxiety, psychosis, depression, and cognitive impairments. This study assessed the consequences of adolescent exposure to EtOH on the behavioral alterations promoted by cocaine withdrawal in adulthood. Methods We pretreated juvenile (34-47 days old) or adult (68-81 days old) mice with EtOH (1.25 g/kg) following a binge-drinking pattern. Then, after a three-week…

MalePhysiologylcsh:MedicineAdolescentsOpen fieldMice0302 clinical medicineCocaineMedicine and Health Scienceslcsh:SciencePrepulse inhibitionmedia_commonMammalsMultidisciplinaryAlcohol ConsumptionAnimal BehaviorDepressionAge FactorsSubstance Withdrawal SyndromeChemistryBehavioral PharmacologyPhysical SciencesVertebratesResearch Articlemedicine.medical_specialtyElevated plus mazeAlcohol Drinkingmedia_common.quotation_subjectBinge drinkingRodents03 medical and health sciencesAlkaloidsInternal medicineRecreational Drug Usemental disordersMental Health and PsychiatrymedicineAnimalsAdultsNutritionPharmacologyBehaviorbusiness.industryMood DisordersBiological LocomotionAddictionlcsh:RChemical CompoundsOrganismsBiology and Life SciencesAbstinenceTail suspension test030227 psychiatryDietEndocrinologyAnxiogenicAge GroupsAmniotesPeople and Placeslcsh:QPopulation GroupingsbusinessZoology030217 neurology & neurosurgeryPloS one
researchProduct